The Biomedical Advanced Research and Development Authority signed a four-year biosecurity contract with GlaxoSmithKline for an anthrax treatment. The deal covers 60,000 doses of raxibacumab.
Published in Brief:
|Vice President of Regulatory Affairs||
|Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX||
|Santa Clara, CA|
|Senior Director, Biostatistics||